Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
19.06
+0.25 (1.33%)
At close: Mar 9, 2026, 4:00 PM EDT
18.69
-0.37 (-1.94%)
After-hours: Mar 9, 2026, 7:49 PM EDT
Aktis Oncology Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 |
| Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Market Capitalization | 1,001 | - | - | - |
| Enterprise Value | 767 | - | - | - |
| Debt / Equity Ratio | 0.06 | 0.05 | 0.13 | 0.01 |
| Debt / FCF Ratio | - | 1.01 | - | - |
| Net Debt / Equity Ratio | -1.17 | -1.16 | -0.81 | -0.97 |
| Net Debt / EBITDA Ratio | 3.31 | 5.65 | 2.51 | 6.57 |
| Net Debt / FCF Ratio | 3.38 | -23.96 | 2.50 | 6.21 |
| Asset Turnover | 0.02 | 0.01 | - | - |
| Quick Ratio | 9.18 | 15.85 | 15.74 | 24.38 |
| Current Ratio | 9.27 | 15.98 | 16.07 | 25.12 |
| Return on Equity (ROE) | -26.50% | -25.18% | -24.42% | - |
| Return on Assets (ROA) | -14.80% | -14.51% | -16.68% | - |
| Return on Capital Employed (ROCE) | -28.90% | -16.90% | -30.00% | -14.90% |
| Buyback Yield / Dilution | -53.35% | -14.46% | -18.90% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.